甲状腺癌中CCDC6-RET与NCOA4-RET融合的临床病理特征:中国人群单中心回顾性队列研究
该单中心回顾性队列研究对2300例中国甲状腺癌病例行二代测序,RET融合仅见于2234例甲状腺乳头状癌(PTC)或分化型高级别甲状腺癌(DHGTC)中的113例(5.06%),其中100例原发灶以CCDC6-RET融合为主(78.0%),NCOA4-RET融合占22.0%。NCOA4-RET融合在45岁及以上患者、DHGTC及淋巴结转移中更常见,CCDC6-RET融合与桥本甲状腺炎及甲状腺球蛋白抗体升高相关;RET融合组复发率高于BRAFV600E突变组(5.0% vs. 0.0%,p=0.018)。
要点
- RET融合仅见于PTC或DHGTC病例,在2234例中占5.06%(113/2234)。
- NCOA4-RET融合与年龄≥45岁、DHGTC及淋巴结转移率更高相关。
- RET融合组复发率5.0%高于BRAFV600E突变组0.0%(p=0.018)。
核心结论
- RET融合在中国甲状腺癌中仅见于PTC或DHGTC病例,CCDC6-RET与NCOA4-RET融合呈现不同的临床病理特征,NCOA4-RET更具侵袭性。
研究设计与样本
- 单中心回顾性队列研究,分析2300例中国甲状腺癌病例,采用二代测序检测福尔马林固定石蜡包埋组织样本。
- 2300例中2234例为PTC或DHGTC,66例为其他类型;2234例中113例(5.06%)存在RET融合,其中100例为原发灶。
主要发现
- 100例原发灶中CCDC6-RET融合占78.0%(78/100),NCOA4-RET融合占22.0%(22/100)。
- NCOA4-RET融合在45岁及以上患者中更常见(54.5% vs. 28.2%,p=0.021),在DHGTC中更常见(p<0.05),淋巴结转移率更高(90.9% vs. 67.9%,p=0.032)。
- CCDC6-RET融合的桥本甲状腺炎患病率更高(67.9% vs. 22.7%,p<0.001),甲状腺球蛋白抗体水平更高(14.11 [1.86-174.32] IU/mL vs. 2.01 [1.14-15.41] IU/mL,p=0.018)。
- CCDC6-RET融合主要见于经典型PTC(56.4%,44/78)和浸润性滤泡型PTC(17.9%,14/78),NCOA4-RET融合更常见于经典型PTC(36.4%,8/22)、实性PTC(27.3%,6/22)和DHGTC(27.3%,6/22)。
- RET融合合并复合突变与年龄≥45岁及双侧甲状腺受累相关;RET融合组复发率高于BRAFV600E突变组(5.0% vs. 0.0%,p=0.018),NCOA4-RET组复发率数值上高于CCDC6-RET组(9.1% vs. 3.8%),但差异无统计学意义(p=0.559)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The rearranged during transfection (RET) proto-oncogene fusion is common in papillary thyroid cancer (PTC), varying across ethnic groups. However, comprehensive comparisons of RET fusion types are limited. This study aims to identify predominant RET fusions and analyze their clinicopathological characteristics in a cohort of Chinese thyroid cancer cases. Methods: This single-center retrospective cohort study analyzed thyroid cancer data, utilizing next-generation sequencing on formalin-fixed, paraffin-embedded tissue samples. Detailed clinicopathological data of thyroid cancer cases with RET fusions were collected. Results: Among 2300 thyroid cancer cases, RET fusions were exclusively found in PTC or differentiated high-grade thyroid carcinoma (DHGTC) cases (2234 cases), absent in other types (66 cases). Of the 2234 PTC or DHGTC cases, 113 (5.06%) exhibited RET fusions, including 100 primary cases. Coiled-coil domain containing 6 (CCDC6)-RET fusions predominated (78.0%, 78/100), with nuclear receptor coactivator 4 (NCOA4)-RET fusions representing 22.0% (22/100). NCOA4-RET fusions were more prevalent in patients aged 45 years and older (54.5% vs. 28.2%, p = 0.021) and DHGTC cases (p < 0.05) and associated with higher rates of lymph node metastases (90.9% vs. 67.9%, p = 0.032). CCDC6-RET fusion exhibited a higher prevalence of Hashimoto's thyroiditis (HT) (67.9% vs. 22.7%, p < 0.001) and elevated thyroglobulin antibody levels (14.11 [1.86-174.32] IU/mL vs. 2.01 [1.14-15.41] IU/mL, p = 0.018). Moreover, CCDC6-RET fusion predominantly occurred in classical PTC (56.4%, 44/78) and infiltrative follicular PTC (17.9%, 14/78), whereas NCOA4-RET fusion was more frequent in classical PTC (36.4%, 8/22), solid PTC (27.3%, 6/22), and DHGTC (27.3%, 6/22). RET fusions with compound mutations were associated with older age (≥45 years) and bilateral thyroid involvement. Follow-up data showed a higher recurrence rate in the RET fusion group compared with the BRAFV600E mutation group (5.0% vs. 0.0%, p = 0.018). Although the NCOA4-RET group showed a numerically higher recurrence rate compared with CCDC6-RET (9.1% vs. 3.8%), this difference was not statistically significant (p = 0.559). Conclusions: RET fusions are specific to PTC or DHGTC cases among Chinese thyroid cancer cases. CCDC6-RET and NCOA4-RET fusions exhibited distinct clinicopathological features, with NCOA4-RET being more aggressive.
引用
- Wang Z, Yao Q, Bao L, et al. Clinicopathological Features of CCDC6-RET and NCOA4-RET Fusions in Thyroid Cancer: A Single-Center Retrospective Cohort Study in a Chinese Population. Thyroid. 2024. PMID: 39212716. doi:10.1089/thy.2024.0151
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。